Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNESP |
Texto Completo: | http://dx.doi.org/10.3390/biomedicines10102398 http://hdl.handle.net/11449/249301 |
Resumo: | As a biologic reservoir of Mycobacterium tuberculosis (M. tb), one-quarter of the world population is infected with the well-known latent tuberculosis (LTBI). About 5–10% of LTBI patients will progress to active disease in the first years after primary infection and, despite using the recommended treatment, 20% can still reactivate the infection. A new LTBI treatment could minimize adverse effects and antibiotic resistance that can occur when the same drug is used to treat the latent and active disease. New hydrazones were evaluated, and they showed great inhibitory activity against intramacrophagic and non-replicating M. tb, commonly found at this stage of infection, in addition to bactericidal and narrow-spectrum activity. When tested against eukaryotic cells, the hydrazones showed great safety at different exposure times. In vitro, these compounds performed better than isoniazid and could be considered new candidates for LTBI treatment, which may promote greater engagement in its prescription and adherence. |
id |
UNSP_87185ef874b85f00cf58a3a0d092ecb2 |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/249301 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacterialatent tuberculosisMycobacterium tuberculosistreatmentAs a biologic reservoir of Mycobacterium tuberculosis (M. tb), one-quarter of the world population is infected with the well-known latent tuberculosis (LTBI). About 5–10% of LTBI patients will progress to active disease in the first years after primary infection and, despite using the recommended treatment, 20% can still reactivate the infection. A new LTBI treatment could minimize adverse effects and antibiotic resistance that can occur when the same drug is used to treat the latent and active disease. New hydrazones were evaluated, and they showed great inhibitory activity against intramacrophagic and non-replicating M. tb, commonly found at this stage of infection, in addition to bactericidal and narrow-spectrum activity. When tested against eukaryotic cells, the hydrazones showed great safety at different exposure times. In vitro, these compounds performed better than isoniazid and could be considered new candidates for LTBI treatment, which may promote greater engagement in its prescription and adherence.Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)Tuberculosis Research Laboratory School of Pharmaceutical Sciences São Paulo State University—UNESPInstitute of Exact Natural Sciences and Education Triangulo Mineiro Federal University—UFTMTuberculosis Research Laboratory School of Pharmaceutical Sciences São Paulo State University—UNESPCNPq: 303603/2018-6Universidade Estadual Paulista (UNESP)Triangulo Mineiro Federal University—UFTMCampos, Débora Leite [UNESP]Demarqui, Fernanda Manaia [UNESP]Solcia, Mariana Cristina [UNESP]de Souza, Paula Carolina [UNESP]da Silva Maia, Pedro IvoDeflon, Victor MarceloPavan, Fernando Rogério [UNESP]2023-07-29T15:12:21Z2023-07-29T15:12:21Z2022-10-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articlehttp://dx.doi.org/10.3390/biomedicines10102398Biomedicines, v. 10, n. 10, 2022.2227-9059http://hdl.handle.net/11449/24930110.3390/biomedicines101023982-s2.0-85140604528Scopusreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengBiomedicinesinfo:eu-repo/semantics/openAccess2024-06-24T13:08:15Zoai:repositorio.unesp.br:11449/249301Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestrepositoriounesp@unesp.bropendoar:29462024-06-24T13:08:15Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria |
title |
Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria |
spellingShingle |
Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria Campos, Débora Leite [UNESP] latent tuberculosis Mycobacterium tuberculosis treatment |
title_short |
Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria |
title_full |
Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria |
title_fullStr |
Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria |
title_full_unstemmed |
Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria |
title_sort |
Latent Tuberculosis: A Promising New Compound to Treat Non-Replicating and Intramacrophagic Mycobacteria |
author |
Campos, Débora Leite [UNESP] |
author_facet |
Campos, Débora Leite [UNESP] Demarqui, Fernanda Manaia [UNESP] Solcia, Mariana Cristina [UNESP] de Souza, Paula Carolina [UNESP] da Silva Maia, Pedro Ivo Deflon, Victor Marcelo Pavan, Fernando Rogério [UNESP] |
author_role |
author |
author2 |
Demarqui, Fernanda Manaia [UNESP] Solcia, Mariana Cristina [UNESP] de Souza, Paula Carolina [UNESP] da Silva Maia, Pedro Ivo Deflon, Victor Marcelo Pavan, Fernando Rogério [UNESP] |
author2_role |
author author author author author author |
dc.contributor.none.fl_str_mv |
Universidade Estadual Paulista (UNESP) Triangulo Mineiro Federal University—UFTM |
dc.contributor.author.fl_str_mv |
Campos, Débora Leite [UNESP] Demarqui, Fernanda Manaia [UNESP] Solcia, Mariana Cristina [UNESP] de Souza, Paula Carolina [UNESP] da Silva Maia, Pedro Ivo Deflon, Victor Marcelo Pavan, Fernando Rogério [UNESP] |
dc.subject.por.fl_str_mv |
latent tuberculosis Mycobacterium tuberculosis treatment |
topic |
latent tuberculosis Mycobacterium tuberculosis treatment |
description |
As a biologic reservoir of Mycobacterium tuberculosis (M. tb), one-quarter of the world population is infected with the well-known latent tuberculosis (LTBI). About 5–10% of LTBI patients will progress to active disease in the first years after primary infection and, despite using the recommended treatment, 20% can still reactivate the infection. A new LTBI treatment could minimize adverse effects and antibiotic resistance that can occur when the same drug is used to treat the latent and active disease. New hydrazones were evaluated, and they showed great inhibitory activity against intramacrophagic and non-replicating M. tb, commonly found at this stage of infection, in addition to bactericidal and narrow-spectrum activity. When tested against eukaryotic cells, the hydrazones showed great safety at different exposure times. In vitro, these compounds performed better than isoniazid and could be considered new candidates for LTBI treatment, which may promote greater engagement in its prescription and adherence. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-10-01 2023-07-29T15:12:21Z 2023-07-29T15:12:21Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.3390/biomedicines10102398 Biomedicines, v. 10, n. 10, 2022. 2227-9059 http://hdl.handle.net/11449/249301 10.3390/biomedicines10102398 2-s2.0-85140604528 |
url |
http://dx.doi.org/10.3390/biomedicines10102398 http://hdl.handle.net/11449/249301 |
identifier_str_mv |
Biomedicines, v. 10, n. 10, 2022. 2227-9059 10.3390/biomedicines10102398 2-s2.0-85140604528 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Biomedicines |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.source.none.fl_str_mv |
Scopus reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
repositoriounesp@unesp.br |
_version_ |
1826304465439817728 |